Skip to main content
. 2012 Mar 13;4:91–97. doi: 10.2147/CMAR.S29672

Figure 1.

Figure 1

Kaplan–Meier estimates of survival of 37 patients with nonsquamous NSCLC, stage IIIB/IV, treated with bevacizumab plus chemotherapy. (A) The median event-free survival was 9.4 months (95% CI: 7.1–11.7) and (B) median overall survival was 21.5 months (95% CI: 12.6–30.5).

Abbreviations: CI, confidence interval; NSCLC, non-small-cell lung cancer.